person · Reporting owner
Kulkarni Sandeep Chidambar
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director · Director and Chairman · 10% owner | July 02, 2026 | August 12, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Director · Chief Executive Officer | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date July 02, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectBy Amanat Sponsor Holdings LLC | 1,875,000 |
Reported balance
After 2026-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-02 · Other · Disposed 281,250 · Balance 1,875,000 F1: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: 281,250 Class B Ordinary Shares were forfeited to the Issuer by Amanat Sponsor Holdings LLC (the "Sponsor") at no cost, in connection with the expiration of the underwriters' over-allotment option as described in the Registration Statement. F3: The Sponsor is the record holder of the securities reported herein. The Reporting Person is the sole managing member of the Sponsor and has voting and investment discretion with respect to the shares held by the Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: 281,250 Class B Ordinary Shares were forfeited to the Issuer by Amanat Sponsor Holdings LLC (the "Sponsor") at no cost, in connection with the expiration of the underwriters' over-allotment option as described in the Registration Statement.
F3: The Sponsor is the record holder of the securities reported herein. The Reporting Person is the sole managing member of the Sponsor and has voting and investment discretion with respect to the shares held by the Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
Zura Bio Ltd
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.03 · Expires 2036-04-01 | Direct | 894,000 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 894,000 · Balance 894,000 F1: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Tourmaline Bio, Inc.
Report date October 28, 2025 · Filed October 28, 2025
Section 16 reporting ended · disclosed 2025-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-10-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-10-28 · Other · Disposed 724,664 · Balance 30,387 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. Row 2 · 2025-10-28 · Disposition to issuer · Disposed 30,387 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3: Pursuant to the terms of the Merger Agreement, each restricted Share outstanding and subject to the Issuer's repurchase right as of immediately prior to the Effective Time became fully vested effective as of immediately prior to the Effective Time, and, by virtue of the merger and net of any applicable withholding taxes, was treated as a Share for all purposes under the terms of the Merger Agreement. |
| Common StockSEC Table I · non-derivative | IndirectBy Gilead Capital, LP | 0 |
Reported balance
After 2025-10-28 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-10-28 · Other · Disposed 7,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. F4: These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.90 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-28 · Disposition to issuer · Disposed 503,478 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.46 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-28 · Disposition to issuer · Disposed 254,207 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.54 | Direct | 0 |
Reported balance
After 2025-10-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-28 · Disposition to issuer · Disposed 226,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share.
F3: Pursuant to the terms of the Merger Agreement, each restricted Share outstanding and subject to the Issuer's repurchase right as of immediately prior to the Effective Time became fully vested effective as of immediately prior to the Effective Time, and, by virtue of the merger and net of any applicable withholding taxes, was treated as a Share for all purposes under the terms of the Merger Agreement.
F4: These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F5: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2026 Filed Aug 12, 2026 11:45 UTC | Amanat Acquisition Corp. AMAN · Entity 6741 | OtherClass B Ordinary Shares · Derivative | 281,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001945691-26-000008 · form4-08122026_110833.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · Director and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Amanat Sponsor Holdings LLC Disclosed balance after: 1,875,000 Underlying: Class A Ordinary Shares · 281,250 shares Expires not disclosed F1 · derivative.exercise_price: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2 · kind: 281,250 Class B Ordinary Shares were forfeited to the Issuer by Amanat Sponsor Holdings LLC (the "Sponsor") at no cost, in connection with the expiration of the underwriters' over-allotment option as described in the Registration Statement. F1 · derivative.exercise_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F1 · derivative.expiration_date: The Class B ordinary shares will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F3 · ownership.nature: The Sponsor is the record holder of the securities reported herein. The Reporting Person is the sole managing member of the Sponsor and has voting and investment discretion with respect to the shares held by the Sponsor. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:16 UTC | Amanat Acquisition Corp. AMAN · Entity 6741 | PurchaseClass A Ordinary Shares | 300,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-060703 · ownership.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · Director and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 300,000 F1 · kind: Reflects the 300,000 private placement shares purchased by Amanat Sponsor Holdings LLC, the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated May 20, 2026 entered into with the Issuer. F1 · price: Reflects the 300,000 private placement shares purchased by Amanat Sponsor Holdings LLC, the Issuer's sponsor, pursuant to the Private Placement Shares Purchase Agreement dated May 20, 2026 entered into with the Issuer. F2 · balance_after: Amanat Sponsor Holdings LLC is the record holder of the securities reported herein. Dr. Sandeep Kulkarni is the sole managing member of our sponsor and has voting and investment discretion with respect to the ordinary shares held of record by Amanat Sponsor Holdings LLC. Dr. Sandeep Kulkarni disclaims any beneficial ownership of the securities held by Amanat Sponsor Holdings LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly. F2 · ownership.nature: Amanat Sponsor Holdings LLC is the record holder of the securities reported herein. Dr. Sandeep Kulkarni is the sole managing member of our sponsor and has voting and investment discretion with respect to the ordinary shares held of record by Amanat Sponsor Holdings LLC. Dr. Sandeep Kulkarni disclaims any beneficial ownership of the securities held by Amanat Sponsor Holdings LLC other than to the extent of any pecuniary interest he may have therein, directly or indirectly. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 22:00 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 894,000 | $0.00 Strike: $6.03 | $0.00 |
DisclosureSEC source: 0001945691-26-000005 · form4-04022026_060413.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 894,000 Underlying: Class A Ordinary Shares · 894,000 shares Expires 2036-04-01 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on April 1, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:56 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 2,934,107 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001945691-26-000003 · form4-01232026_100132.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,934,107 Underlying: Class A Ordinary Shares · 2,934,107 shares Expires 2036-01-21 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on January 21, 2027, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 226,000 | Not disclosed Strike: $15.54 | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · derivative · entry 6 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 226,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 254,207 | Not disclosed Strike: $9.46 | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · derivative · entry 5 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 254,207 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 503,478 | Not disclosed Strike: $7.90 | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · derivative · entry 4 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 503,478 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F5 · price: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each stock option that was outstanding and unexercised immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the amount by which the Merger Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares issuable upon exercise of such option or portion thereof, subject to any applicable withholding of taxes. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | OtherCommon Stock | 7,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · nonDerivative · entry 3 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Gilead Capital, LP Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2 · price: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. F4 · ownership.nature: These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Disposition to issuerCommon Stock | 30,387 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · nonDerivative · entry 2 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F3 · price: Pursuant to the terms of the Merger Agreement, each restricted Share outstanding and subject to the Issuer's repurchase right as of immediately prior to the Effective Time became fully vested effective as of immediately prior to the Effective Time, and, by virtue of the merger and net of any applicable withholding taxes, was treated as a Share for all purposes under the terms of the Merger Agreement. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 22:30 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | OtherCommon Stock | 724,664 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001945691-25-000006 · form4-10282025_061001.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,387 F1 · kind: This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 8, 2025, by and among Issuer, Novartis AG, a company limited by shares (Aktiengesellschaft) incorporated under the laws of Switzerland ("Parent"), and Torino Merger Sub Inc., a Delaware corporation and indirect wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on October 28, 2025, Merger Sub completed a cash tender offer to acquire all of the shares of common stock of the Issuer, par value $0.0001 (the "Shares"), issued and outstanding immediately prior to the effective time of the merger (the "Effective Time"), in exchange for $48.00 in cash per Share, subject to any applicable withholding of taxes (the "Merger Consideration"). F2 · price: Pursuant to the terms of the Merger Agreement, each Share was tendered in exchange for $48.00 in cash per Share. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:05 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 25,316 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001945691-25-000004 · form4-10242025_091030.xml · derivative · entry 3 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 503,478 Underlying: Common Stock · 25,316 shares Expires 2033-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option vested as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 21:05 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | Exercise / conversionCommon Stock | 25,316 | $7.90 | $199,996.40 |
DisclosureSEC source: 0001945691-25-000004 · form4-10242025_091030.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2025 Filed May 22, 2025 21:36 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001415889-25-014221 · form4-05222025_090521.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,000 Underlying: Class A Ordinary Shares · 51,000 shares Expires 2035-05-21 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from May 21, 2025; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:19 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantEmployee Stock Option (Right to Buy) · Derivative | 226,000 | $0.00 Strike: $15.54 | $0.00 |
DisclosureSEC source: 0001827506-25-000014 · wk-form4_1738703938.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on February 3, 2026, with the remainder vesting in 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 21:45 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantShare Option (Right to Buy) · Derivative | 117,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028975 · form4-12112024_041209.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,000 Underlying: Class A Ordinary Shares · 117,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: This option vests in twelve substantially equal monthly installments over a one-year period measured from October 23, 2024; provided, that any remaining unvested portion of the option award will vest as of the day immediately preceding the next annual meeting of shareholders following the grant date, subject to the Reporting Person's continued service as of each such vesting date. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 20:22 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 1,779 | $14.85 | $26,418.15 |
DisclosureSEC source: 0001827506-24-000076 · wk-form4_1724358128.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Gilead Capital, LP Disclosed balance after: 7,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.82 to $14.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:09 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 5,221 | $13.79 | $71,997.59 |
DisclosureSEC source: 0001827506-24-000074 · wk-form4_1724191780.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Gilead Capital, LP Disclosed balance after: 5,221 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.77 to $13.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.nature: These shares are held by Gilead Capital, LP ("Gilead"). The Reporting Person's spouse is a partner of Gilead and shares voting and investment power with respect to the shares held by Gilead, and therefore the Reporting Person may be deemed an indirect beneficial owner of these shares. This report is not an admission that the Reporting Person is an indirect beneficial owner of these shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 23:15 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 4,000 | $16.99 | $67,960.00 |
DisclosureSEC source: 0001209191-23-056128 · doc4.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,735 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.96 to $17.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| October 26, 2023 Filed Oct 26, 2023 21:34 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 5,000 | $12.25 | $61,250.00 |
DisclosureSEC source: 0001209191-23-053691 · doc4.xml · nonDerivative · entry 2 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725,735 Read SEC document |
| October 24, 2023 Filed Oct 26, 2023 21:34 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | PurchaseCommon Stock | 4,650 | $10.68 | $49,662.00 |
DisclosureSEC source: 0001209191-23-053691 · doc4.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 720,735 Read SEC document |
| October 23, 2023 Filed Oct 24, 2023 00:25 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantEmployee Stock Option (Right to Buy) · Derivative | 254,207 | $0.00 Strike: $9.46 | $0.00 |
DisclosureSEC source: 0001209191-23-053399 · doc4.xml · derivative · entry 3 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,207 Underlying: Common Stock · 254,207 shares Expires 2033-10-22 F6 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on October 23, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 19, 2023 Filed Oct 24, 2023 00:25 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantEmployee Stock Option (Right to Buy) · Derivative | 528,794 | Not disclosed Strike: $7.90 | Not disclosed |
DisclosureSEC source: 0001209191-23-053399 · doc4.xml · derivative · entry 2 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 528,794 Underlying: Common Stock · 528,794 shares Expires 2033-06-17 F3 · derivative.exercise_price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F3 · price: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. F5 · price: Received in exchange for a stock option to acquire 6,629,000 shares of Tourmaline common stock pursuant to the Merger Agreement. F4 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 14, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. F3 · derivative.underlying_shares: Upon the closing of the Merger, each outstanding option to purchase shares of Tourmaline common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock, on the same terms and conditions as were applicable to such Tourmaline stock option prior to the Merger, as adjusted for the exchange ratio and the reverse stock split. Read SEC document |
| October 19, 2023 Filed Oct 24, 2023 00:25 UTC | Tourmaline Bio, Inc. TRML · Entity 15643 | GrantCommon Stock | 716,085 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053399 · doc4.xml · nonDerivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 716,085 F1 · shares: 134,591 of these shares are subject to a repurchase option in favor of the Issuer in the event that the Reporting Person's continuous service is terminated. Such repurchase option shall lapse in equal monthly installments until such shares are fully vested on June 1, 2026. F2 · price: Received in exchange for 8,976,874 shares of common stock of Tourmaline Bio, Inc. ("Tourmaline") pursuant to an Agreement and Plan of Merger dated as of June 22, 2023 (the "Merger Agreement") by and among Tourmaline, the Issuer and Terrain Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on October 19, 2023, Merger Sub merged with and into Tourmaline (the "Merger"), with Tourmaline surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Tourmaline common stock was converted into the right to receive 0.07977 of a share of the Issuer's common stock, after giving effect to a reverse stock split of the Issuer's common stock of 10-for-1. Subsequent to the Merger, the name of the Issuer was changed from Talaris Therapeutics, Inc. to Tourmaline Bio, Inc. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:17 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 207,520 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0001104659-23-063318 · tm2316481-7_4seq1.xml · derivative · entry 1 Kulkarni Sandeep Chidambar · CIK 0001945691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207,520 Underlying: Class A Ordinary Shares · 207,520 shares Expires 2033-05-18 F1 · derivative.exercise_date: 25% of the option shall become exercisable on May 18, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.